FORA Capital’s KalVista Pharmaceuticals KALV Stock Holding History

FORA Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,791	Closed	-$46K	–	1016
2021 Q1	$46K	Buy	+1,791	New	+$47.1K	0.02%	555

Other funds holding KALV

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FORA Capital's KALV Position: Q2 2021 in Review

FORA Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2021, closing a stake of 1,791 shares — an estimated $46K sold.

FORA Capital first reported a position in KALV in Q1 2021 and held it in 1 quarter. The position peaked at $46K in Q1 2021. 110 funds tracked by Wall St. Rank hold KALV as of Q2 2021.

FORA Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
FORA Capital sold 1,791 KalVista Pharmaceuticals shares in Q2 2021, an estimated $46K.
FORA Capital first reported a position in KalVista Pharmaceuticals in Q1 2021 and held it in 1 quarter.
FORA Capital's KalVista Pharmaceuticals position peaked at $46K in Q1 2021.
110 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2021.

Based on FORA Capital's 13F filing for Q2 2021, filed 16 Aug 2021.